ISO 15378:2017 - Primary Packaging for Medicines Lead Auditor Free Practice Test — 30 Questions

Question 1

During an audit of a primary packaging manufacturer for medicinal products, a significant non-conformity was identified concerning an unacceptable level of particulate contamination found in a batch of glass vials. The manufacturer implemented a corrective action plan, which included enhanced cleaning procedures for the vial washing equipment and stricter visual inspection protocols for incoming raw materials. As a lead auditor, which of the following approaches would provide the most robust evidence that the corrective action has effectively prevented the recurrence of this specific non-conformity?

Accepted Answer

Conducting a follow-up audit focused on the vial washing process and re-testing a statistically significant sample of vials from subsequent production batches under conditions that previously revealed the contamination.

Question 2

During an audit of a primary packaging material manufacturer for pharmaceutical products, an auditor observes that while the manufacturing process for a critical plastic component is documented, the specific critical process parameters (CPPs) and their acceptable ranges, which directly influence the component\'s leachables profile and dimensional stability, are not explicitly defined or controlled within the documented procedures. The company relies on general operator experience to maintain consistency. What is the most appropriate action for the auditor to take in this situation, considering the requirements of ISO 15378:2017?

Accepted Answer

Document the absence of defined critical process parameters and their control limits as a nonconformity and verify the implementation of corrective actions to establish and document these parameters.

Question 3

During an audit of a primary packaging material manufacturer for sterile ophthalmic solutions, an auditor reviews the process control documentation for the critical parameter of melt viscosity during the extrusion of a specific polymer film. The manufacturer\'s records indicate that this parameter has been controlled within a defined range for the past five years, based on initial process validation studies. However, there is no recent documented risk assessment or re-validation data to confirm that this specific melt viscosity range remains critical for preventing particulate contamination and ensuring the dimensional stability of the film, nor is there evidence of ongoing statistical process control demonstrating consistent adherence to these limits. Which of the following represents the most appropriate auditor action to assess the effectiveness of the QMS in this situation?

Accepted Answer

Request evidence of a current risk assessment and validation or re-validation study that confirms the criticality of the melt viscosity parameter and the appropriateness of the established control limits, along with evidence of ongoing monitoring and statistical analysis demonstrating process stability.

Question 4

When auditing a manufacturer of primary packaging for sterile injectable medicines, specifically focusing on the control of critical process parameters, what is the lead auditor\'s primary objective regarding documented procedures for sterilization and aseptic filling?

Accepted Answer

To verify that the documented procedures for sterilization and aseptic filling are not only established but also demonstrably implemented and effective in controlling identified critical parameters, with evidence of validation and continuous monitoring.

Question 5

During an audit of a primary packaging material supplier for sterile injectable medicines, an auditor reviews a recent deviation report detailing an unusually high particulate count detected in a batch of glass vials. The supplier\'s internal investigation indicates the particulates are primarily inorganic and originate from a specific stage in the glass melting process. Considering the requirements of ISO 15378:2017 for risk management and contamination control, what is the most critical aspect for the auditor to evaluate regarding the supplier\'s response to this deviation?

Accepted Answer

The thoroughness of the supplier's risk assessment to determine the potential impact of these particulates on the sterility and efficacy of the final medicinal product, and the effectiveness of implemented containment and corrective actions.

Question 6

During an audit of a pharmaceutical company that uses specialized glass vials for a sensitive biologic drug, the lead auditor identifies that the supplier\'s documented risk assessment for a particular vial coating process appears to lack a systematic approach to identifying and evaluating potential leachables that could impact drug stability. The supplier has provided a general risk assessment for their overall manufacturing process but has not detailed the specific risks associated with this coating application. What is the most appropriate course of action for the lead auditor to ensure compliance with ISO 15378:2017, particularly concerning the supplier\'s risk management responsibilities for primary packaging materials?

Accepted Answer

Request documented evidence that the supplier has implemented a comprehensive, risk-based approach to identify, evaluate, and control potential hazards and risks associated with the specific vial coating process, including a detailed risk assessment for leachables.

Question 7

During an audit of a pharmaceutical company that uses specialized Type I borosilicate glass vials for sterile injectable products, the lead auditor discovers that a key supplier has recently altered the annealing temperature profile for these vials due to a process optimization initiative. The supplier provided a notification to the pharmaceutical company\'s procurement department, but no formal change control process was initiated by the pharmaceutical manufacturer for this specific material modification. What is the most critical deficiency an auditor should identify in this scenario concerning ISO 15378:2017 requirements?

Accepted Answer

Lack of a documented risk assessment and subsequent re-qualification or validation by the pharmaceutical manufacturer to confirm the continued suitability of the modified glass vials for their intended use.

Question 8

During an audit of a pharmaceutical company\'s primary packaging supplier, an auditor identifies that the supplier\'s documented risk assessment for a critical component, a sterile glass vial, does not explicitly detail the methodology for evaluating potential microbial ingress during the annealing process. However, the supplier\'s quality records indicate no reported instances of microbial contamination in the finished vials over the past five years. What is the lead auditor\'s primary responsibility in this scenario, considering the requirements of ISO 15378:2017 regarding risk management and contamination control?

Accepted Answer

Verify the supplier's risk management process for the annealing stage, seeking evidence of how potential microbial ingress is assessed and controlled, and evaluate the effectiveness of implemented controls despite the absence of documented specific methodology.

Question 9

During an audit of a primary packaging material supplier for sterile injectable drug products, an auditor is reviewing the risk management process for a critical component: a silicone-coated rubber stopper. The supplier\'s documentation indicates a risk assessment was performed, identifying potential particulate contamination from the coating process. However, the assessment does not explicitly detail the evaluation of microbial ingress risks through the stopper\'s surface or the potential for leachables from the silicone coating that could affect drug stability. What is the lead auditor\'s primary responsibility in this scenario concerning the supplier\'s adherence to ISO 15378:2017, Clause 7.1.2?

Accepted Answer

Verify that the supplier's risk management process comprehensively addresses all potential contamination pathways, including microbial ingress and chemical leachables, for the critical stopper component, and that implemented controls are effective.

Question 10

During an audit of a primary packaging material supplier for pharmaceutical products, an auditor is evaluating the effectiveness of the supplier\'s risk management process as required by ISO 15378:2017. The supplier has provided a comprehensive risk management plan and a register of identified risks. Which of the following audit activities would most effectively verify the *implementation* and *effectiveness* of this risk management system?

Accepted Answer

Reviewing the supplier's documented risk management procedure and the risk register for completeness and adherence to the standard's requirements.

Question 11

During an audit of a pharmaceutical packaging facility, an auditor discovers that a critical polymer film used in blister packs has been switched to a new supplier due to cost-saving initiatives. The new supplier\'s material has undergone internal testing, but no formal risk assessment or validation study specifically addressing the impact on the drug product\'s shelf-life or potential for extractables and leachables has been completed and documented prior to the change being implemented. Which aspect of ISO 15378:2017 is most directly contravened by this action?

Accepted Answer

The requirement for a documented risk-based approach to change control for any modification impacting product quality.

Question 12

During an audit of a facility manufacturing primary packaging for sterile injectable medicines, an auditor is reviewing the process validation documentation for a critical component. The facility has identified several process parameters but has not explicitly linked them to their potential impact on the sterile barrier integrity or leachables profile. What is the most crucial aspect for the lead auditor to verify regarding the control of these parameters to ensure compliance with ISO 15378:2017 and patient safety?

Accepted Answer

Evidence that critical process parameters (CPPs) have been identified and their acceptable ranges established based on risk assessment and their impact on product quality attributes, with documented monitoring and control strategies in place.

Question 13

Consider a scenario where an audit of a pharmaceutical company\'s primary packaging supplier reveals a past incident involving a cleaning agent spill in a non-product contact area of the supplier\'s warehouse. The spill was reportedly contained, and the supplier has provided documentation of their corrective actions. As a lead auditor for ISO 15378:2017, how would you most effectively verify the adequacy of the pharmaceutical company\'s risk management system concerning this incident and its potential impact on the primary packaging materials supplied?

Accepted Answer

Review the pharmaceutical company's documented risk assessment for this supplier, focusing on how the incident was evaluated, the residual risk determined, and the preventive controls implemented or verified to mitigate any potential contamination.

Question 14

During an audit of a primary packaging material supplier for pharmaceutical products, how should a lead auditor most effectively assess the supplier\'s adherence to the risk management requirements outlined in ISO 15378:2017, particularly concerning the potential impact of material variations on drug product stability and patient safety?

Accepted Answer

Evaluate the supplier's documented risk management process, verify the identification and assessment of risks related to material properties and manufacturing processes, and review evidence of implemented control measures and their ongoing effectiveness through validation and monitoring records.

Question 15

Consider a pharmaceutical manufacturer preparing to qualify a new supplier for sterile elastomeric stoppers intended for parenteral drug products. The manufacturer\'s quality assurance team is tasked with ensuring compliance with ISO 15378:2017, particularly regarding contamination control. Which approach best demonstrates a robust risk-based strategy for mitigating potential contamination risks introduced by this new supplier?

Accepted Answer

Conducting a comprehensive risk assessment of the supplier's manufacturing processes, environmental controls, and quality management system, followed by implementing specific controls based on identified risks.

Question 16

During an audit of a primary packaging material manufacturer for medicinal products, an auditor is assessing the effectiveness of the organization\'s controls over external providers as mandated by ISO 15378:2017. The organization has a documented procedure for supplier selection and evaluation. What specific evidence would most strongly demonstrate the *effectiveness* of this control mechanism, beyond mere procedural compliance?

Accepted Answer

Records of supplier performance reviews, including documented communication of identified issues and subsequent corrective actions taken by the supplier.

Question 17

During an audit of a primary packaging manufacturer for sterile ophthalmic solutions, an auditor reviews the risk assessment documentation for particulate contamination of glass vials. The manufacturer has identified potential sources such as airborne particles during filling and residual cleaning agents. However, the auditor notes a lack of detailed investigation into the risk posed by leachables from the vial stoppers under specific storage conditions, or the potential for microbial ingress through microscopic imperfections in the vial neck finish that might not be visually apparent. Which of the following best describes the auditor\'s finding regarding the manufacturer\'s risk management process for this critical aspect?

Accepted Answer

The risk assessment is incomplete as it fails to comprehensively address all plausible contamination pathways and associated control measures, particularly concerning material leachables and subtle physical defects.

Question 18

During an audit of a primary packaging manufacturer supplying sterile glass vials for parenteral drugs, an auditor observes that the supplier\'s risk management documentation for potential particulate contamination primarily focuses on the final visual inspection stage. The supplier asserts that this is sufficient as any significant contamination would be caught before release. Which aspect of the ISO 15378:2017 standard, specifically concerning risk management for product safety, is most likely being inadequately addressed by the supplier\'s approach?

Accepted Answer

The systematic identification and evaluation of potential contamination sources throughout the entire manufacturing process, from raw material receipt to final packaging.

Question 19

During an audit of a facility manufacturing primary packaging for sterile injectable medications, an auditor observes that while the sterilization validation report for ethylene oxide sterilization confirms the process parameters (temperature, humidity, gas concentration, exposure time) are effective, the routine batch records for several recent production runs show inconsistent recording of these critical parameters. Specifically, temperature logs are sometimes incomplete, and the precise gas concentration readings are not always documented. What is the most appropriate auditor conclusion and action regarding this observation in the context of ISO 15378:2017?

Accepted Answer

Identify a nonconformity related to inadequate process control and validation evidence, requiring the organization to implement robust monitoring and recording procedures for critical sterilization parameters.

Question 20

During an audit of a manufacturer producing primary packaging components for parenteral drug products, an auditor reviews the process control records for a critical molding step. The records show consistent monitoring of injection pressure and temperature within specified limits. However, the auditor notes a lack of documented evidence demonstrating the validation of the molding process itself to ensure consistent dimensional accuracy and absence of microscopic defects that could compromise sterility. Which of the following represents the most significant audit finding concerning ISO 15378:2017 compliance?

Accepted Answer

Absence of documented process validation to confirm the consistent achievement of critical quality attributes for the primary packaging component.

Question 21

During an audit of a primary packaging manufacturer supplying sterile injectables, an auditor is reviewing the process for controlling critical-to-quality characteristics (CTQCs) of glass vials. The manufacturer has identified several CTQCs, including dimensional tolerances, surface integrity, and particulate contamination levels. Which of the following audit activities would most effectively verify the robustness of the organization\'s risk-based approach to managing these CTQCs in accordance with ISO 15378:2017?

Accepted Answer

Reviewing the documented risk management procedure and examining evidence of its application to the identified CTQCs, including risk assessments and implemented control measures.

Question 22

During an audit of a primary packaging manufacturer for sterile injectable drug products, an auditor is reviewing the process for producing glass vials. The manufacturer has identified several critical process parameters (CPPs) for glass forming, including melt temperature, mold pressure, and cooling rate. Which of the following represents the most thorough approach for the auditor to verify the effectiveness of the manufacturer\'s control strategy for these CPPs, ensuring compliance with ISO 15378:2017 requirements for process control and product safety?

Accepted Answer

Reviewing the documented process validation reports for the glass forming process, examining statistical process control (SPC) data for the identified CPPs, and verifying records of calibration for critical monitoring equipment.

Question 23

During an audit of a primary packaging material supplier for injectable pharmaceuticals, an auditor observes that the supplier\'s documented risk management procedure for potential particulate contamination is comprehensive. However, the supplier\'s recent internal audit report highlights several instances where the supplier failed to consistently implement the specified cleaning validation protocols for critical processing equipment used in the manufacturing of sterile glass vials. What is the lead auditor\'s primary responsibility in this situation concerning the supplier\'s adherence to ISO 15378:2017 requirements?

Accepted Answer

To verify that the supplier has initiated corrective actions to address the non-conformities identified in their internal audit regarding cleaning validation, and to assess the effectiveness of these actions in preventing future contamination.

Question 24

During an audit of a primary packaging material manufacturer for sterile injectable drug products, an auditor is reviewing the controls for a critical parameter, such as the residual solvent content in a specific polymer film. The manufacturer has documented specifications for this residual solvent and has implemented a process for monitoring it on each production batch. However, the auditor notes that the scientific rationale and validation data supporting the *establishment* of the specific acceptable limit for this residual solvent are not readily available or appear to be based on outdated industry guidelines without specific product-specific risk assessment. What is the most critical area the lead auditor must focus on to ensure the effectiveness of the Quality Management System in this context, according to ISO 15378:2017 principles?

Accepted Answer

Verification of the validation studies that underpin the scientific justification for the established acceptable limits of critical process parameters.

Question 25

During an audit of a primary packaging manufacturer for pharmaceutical products, an auditor observes that a critical sealing parameter for a blister pack, previously validated to operate within a range of $150^\circ\text{C}$ to $160^\circ\text{C}$, was inadvertently set to $145^\circ\text{C}$ for a specific production run. The packaging material is a sensitive polymer requiring precise temperature control to maintain its barrier properties and seal integrity. What is the most immediate and critical action the auditor should expect the auditee to take in response to this deviation, considering the requirements of ISO 15378:2017?

Accepted Answer

Quarantine the entire batch of finished product packaged during the period the deviation occurred.

Question 26

During an audit of a primary packaging manufacturer for injectable medicines, an auditor discovers that a supplier of Type I borosilicate glass vials has proposed a minor alteration to the glass composition, citing improved thermal resistance. The manufacturer has documented this change internally and proceeded with its implementation without a comprehensive risk assessment or validation study specifically addressing potential impacts on extractables and leachables profiles relevant to the drug product. Which of the following represents the most significant non-conformity against the principles of ISO 15378:2017 for a lead auditor to identify?

Accepted Answer

Failure to conduct a thorough risk assessment and validation study to confirm the suitability of the altered glass composition for direct contact with medicinal products, potentially impacting extractables and leachables.

Question 27

During an audit of a primary packaging material supplier for a pharmaceutical company, an auditor is evaluating the supplier\'s adherence to ISO 15378:2017. The supplier has a documented risk management procedure, but the auditor suspects its practical application may be superficial. What is the most critical aspect for the lead auditor to verify to ensure compliance and effective risk mitigation for medicinal product integrity?

Accepted Answer

The systematic implementation and documented evidence of risk analysis, evaluation, and control measures for identified packaging material risks.

Question 28

During an audit of a primary packaging manufacturer for medicinal products, an auditor identifies a batch of glass vials that exhibit a slight, but consistent, variation in wall thickness, falling just outside the tighter internal specification but still within the pharmacopoeial limits. The manufacturer has segregated this batch and initiated a nonconformity report. What is the most critical aspect for the auditor to verify regarding the manufacturer\'s response to this situation to ensure compliance with ISO 15378:2017?

Accepted Answer

Confirmation that a thorough root cause analysis has been conducted and that implemented corrective actions are demonstrably effective in preventing recurrence of the wall thickness variation.

Question 29

During an audit of a primary packaging manufacturer for parenteral drug products, you observe a minor, uncontained spill of a cleaning agent in a secondary processing area, adjacent to where sterile stoppers are being inspected. The manufacturer\'s quality manager states that the cleaning agent is non-toxic and poses no risk to the packaging materials. As a lead auditor, what is the most appropriate immediate action regarding this observation?

Accepted Answer

Assess the effectiveness of the manufacturer's documented procedures for spill containment, cleaning agent segregation, and environmental monitoring to prevent potential contamination of packaging materials.

Question 30

During an audit of a primary packaging material manufacturer for sterile injectable drug products, an auditor reviews the process control documentation for the extrusion of a critical polymer film. The manufacturer has identified melt temperature and extrusion speed as critical process parameters (CPPs). While the manufacturer has established nominal operating ranges for these parameters, the audit reveals a lack of documented validation studies demonstrating how these specific ranges were determined to ensure the film\'s barrier properties and absence of leachables meet the stringent requirements of pharmacopoeial monographs and relevant Good Manufacturing Practices (GMPs). Furthermore, the procedure for handling deviations from these ranges is primarily reactive, focusing on immediate correction rather than thorough root cause analysis and impact assessment. Which of the following findings represents the most significant deficiency in the manufacturer\'s Quality Management System concerning ISO 15378:2017 requirements for process control?

Accepted Answer

Insufficient documented validation of the established operating ranges for critical process parameters, coupled with a reactive approach to deviation management.

ISO 15378:2017 - Primary Packaging for Medicines Lead Auditor Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 15378:2017 - Primary Packaging for Medicines Lead Auditor Certification